Related Experiment Video
Updated: Jul 23, 2025
05:31
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
10.4K
Circulating MicroRNAs associated with Bronchodilator Response in Childhood Asthma
Rinku Sharma1, Anshul Tiwari2, Alvin T Kho1
1Brigham and Women's Hospital and Harvard Medical School.
Research Square
|July 18, 2023
Summary
Two specific microRNAs, miR-1246 and miR-200b-3p, are linked to bronchodilator response (BDR) in both children and adults with asthma. These findings highlight the role of microRNAs in varying asthma treatment responses.
Area of Science:
- Pulmonary Medicine
- Genetics
- Molecular Biology
Background:
- Bronchodilator response (BDR) in asthma varies significantly among patients.
- MicroRNAs (miRNAs) are key post-translational regulators with potential roles in asthma pathophysiology.
- Understanding the molecular basis of BDR variation is crucial for personalized asthma management.
Approach:
- Small RNA sequencing was performed on serum from 1,134 children with asthma (Genetics of Asthma in Costa Rica Study).
- Differential expression analysis identified miRNAs associated with high vs. low BDR.
- Replication analysis was conducted in an adult asthma cohort (LOCCS).
- Functional annotation and pathway enrichment analysis were performed on differentially expressed miRNAs.
Key Points:
- Ten down-regulated and one up-regulated miRNA were identified between high and low BDR groups in children.
- Two miRNAs, miR-200b-3p and miR-1246, were successfully replicated in the adult cohort.
- Enriched pathways included cholesterol biosynthesis, ESR-mediated signaling, and TGF-beta signaling.
Conclusions:
- miR-1246 and miR-200b-3p are associated with BDR in both pediatric and adult asthma.
- These findings underscore the significant role of miRNAs in mediating differential treatment responses in asthma.
- This research provides insights into the genomic regulatory mechanisms underlying BDR variation.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
450
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
450
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
311
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
311
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
499
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
499
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
351
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
351
01:19Antiasthma Drugs: Leukotriene Modifiers
368
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
368